MiNK's INKT Cell Therapy Shows Potential For Optimal Multi-Combination For Resistant Solid Cancers At SITC 2024; PRAME-TCR INKT Overcomes Challenges From Conventional TCR-T Cells In Solid Cancers
MiNK's INKT Cell Therapy Shows Potential For Optimal Multi-Combination For Resistant Solid Cancers At SITC 2024; PRAME-TCR INKT Overcomes Challenges From Conventional TCR-T Cells In Solid Cancers
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit
第797代理物与检查点抑制剂和双特异性结合剂共同扩大抗癌效果
PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers
PRAME-TCR iNKt克服了固体癌症中传统TCR-t细胞面临的挑战
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK's iNKT cell therapy programs, agenT-797 and PRAME-TCR.
纽约，2024年11月7日（环球新闻社）-- MiNk Therapeutics，Inc.（纳斯达克: INKT）是一家临床阶段的生物制药公司，致力于发现、开发和推广异基因、现成的不变自然杀伤T（iNKT）细胞疗法，以治疗癌症和其他免疫介导的疾病。该公司今天在德克萨斯州休斯顿举行的第39届美国免疫疗法学会（SITC）年会上宣布了来自两个海报展示的数据。这些展示展示了来自MiNK的iNKt细胞疗法项目agent-797和PRAME-TCR的新数据。
